Cargando…

CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies

Dipeptidyl peptidase IV (DPP-IV) inhibitor has been expected to be a new class of anti-diabetic agent. The present study was designed to characterize the pharmacological profiles of CMD-05, a novel DPP-IV inhibitor discovered in our laboratory, in vitro and in vivo. The IC(50) of CMD-05 on DPP-IV in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jie, Li, Huan, Hu, Xiangnan, Yang, Lu, Chen, Qi, Hu, Congli, Chen, Zhihao, Tian, Xiaoyan, Yang, Yang, Luo, Ying, Gan, Run, Yang, Junqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390258/
https://www.ncbi.nlm.nih.gov/pubmed/28406239
http://dx.doi.org/10.1038/srep46628
_version_ 1782521422861565952
author Ma, Jie
Li, Huan
Hu, Xiangnan
Yang, Lu
Chen, Qi
Hu, Congli
Chen, Zhihao
Tian, Xiaoyan
Yang, Yang
Luo, Ying
Gan, Run
Yang, Junqing
author_facet Ma, Jie
Li, Huan
Hu, Xiangnan
Yang, Lu
Chen, Qi
Hu, Congli
Chen, Zhihao
Tian, Xiaoyan
Yang, Yang
Luo, Ying
Gan, Run
Yang, Junqing
author_sort Ma, Jie
collection PubMed
description Dipeptidyl peptidase IV (DPP-IV) inhibitor has been expected to be a new class of anti-diabetic agent. The present study was designed to characterize the pharmacological profiles of CMD-05, a novel DPP-IV inhibitor discovered in our laboratory, in vitro and in vivo. The IC(50) of CMD-05 on DPP-IV inhibitory activity was approximately 12 nM while vildagliptin was 3.5 nM in vitro. In diabetes rat model established by high fat diet/low dose streptozotocin, CMD-05 inhibited DPP-IV activity, significantly improved glucose tolerance, increased GLP-1 and insulin levels in plasma. Long-term administration of CMD-05 decreased HbA1c and TG levels and improved the islet function without significantly effect on body weight. Furthermore, CMD-05 reduced INS-1 cell apoptosis and increased GLP-1 secretion in NCI-H716. After oral administration, CMD-05 reached peak concentration at 30 min with half-life of 288 minutes and the inhibitory rate of DPP-IV greater than 50% lasted for 15 h. In fasted normal rats, CMD-05 didn’t cause significant hypoglycemia. CMD-05 had a lower cytotoxicity than vildagliptin in vitro and its maximum tolerance dose in mice is beyond 2000 mg/kg. These results indicated that CMD-05 has similar activity with vildagliptin in vivo and has a much longer half-life and lower cytotoxicity than vildagliptin.
format Online
Article
Text
id pubmed-5390258
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53902582017-04-14 CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies Ma, Jie Li, Huan Hu, Xiangnan Yang, Lu Chen, Qi Hu, Congli Chen, Zhihao Tian, Xiaoyan Yang, Yang Luo, Ying Gan, Run Yang, Junqing Sci Rep Article Dipeptidyl peptidase IV (DPP-IV) inhibitor has been expected to be a new class of anti-diabetic agent. The present study was designed to characterize the pharmacological profiles of CMD-05, a novel DPP-IV inhibitor discovered in our laboratory, in vitro and in vivo. The IC(50) of CMD-05 on DPP-IV inhibitory activity was approximately 12 nM while vildagliptin was 3.5 nM in vitro. In diabetes rat model established by high fat diet/low dose streptozotocin, CMD-05 inhibited DPP-IV activity, significantly improved glucose tolerance, increased GLP-1 and insulin levels in plasma. Long-term administration of CMD-05 decreased HbA1c and TG levels and improved the islet function without significantly effect on body weight. Furthermore, CMD-05 reduced INS-1 cell apoptosis and increased GLP-1 secretion in NCI-H716. After oral administration, CMD-05 reached peak concentration at 30 min with half-life of 288 minutes and the inhibitory rate of DPP-IV greater than 50% lasted for 15 h. In fasted normal rats, CMD-05 didn’t cause significant hypoglycemia. CMD-05 had a lower cytotoxicity than vildagliptin in vitro and its maximum tolerance dose in mice is beyond 2000 mg/kg. These results indicated that CMD-05 has similar activity with vildagliptin in vivo and has a much longer half-life and lower cytotoxicity than vildagliptin. Nature Publishing Group 2017-04-13 /pmc/articles/PMC5390258/ /pubmed/28406239 http://dx.doi.org/10.1038/srep46628 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Ma, Jie
Li, Huan
Hu, Xiangnan
Yang, Lu
Chen, Qi
Hu, Congli
Chen, Zhihao
Tian, Xiaoyan
Yang, Yang
Luo, Ying
Gan, Run
Yang, Junqing
CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies
title CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies
title_full CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies
title_fullStr CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies
title_full_unstemmed CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies
title_short CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies
title_sort cmd-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390258/
https://www.ncbi.nlm.nih.gov/pubmed/28406239
http://dx.doi.org/10.1038/srep46628
work_keys_str_mv AT majie cmd05anovelpromisingclinicalantidiabeticdrugcandidateinvivoandvitrostudies
AT lihuan cmd05anovelpromisingclinicalantidiabeticdrugcandidateinvivoandvitrostudies
AT huxiangnan cmd05anovelpromisingclinicalantidiabeticdrugcandidateinvivoandvitrostudies
AT yanglu cmd05anovelpromisingclinicalantidiabeticdrugcandidateinvivoandvitrostudies
AT chenqi cmd05anovelpromisingclinicalantidiabeticdrugcandidateinvivoandvitrostudies
AT hucongli cmd05anovelpromisingclinicalantidiabeticdrugcandidateinvivoandvitrostudies
AT chenzhihao cmd05anovelpromisingclinicalantidiabeticdrugcandidateinvivoandvitrostudies
AT tianxiaoyan cmd05anovelpromisingclinicalantidiabeticdrugcandidateinvivoandvitrostudies
AT yangyang cmd05anovelpromisingclinicalantidiabeticdrugcandidateinvivoandvitrostudies
AT luoying cmd05anovelpromisingclinicalantidiabeticdrugcandidateinvivoandvitrostudies
AT ganrun cmd05anovelpromisingclinicalantidiabeticdrugcandidateinvivoandvitrostudies
AT yangjunqing cmd05anovelpromisingclinicalantidiabeticdrugcandidateinvivoandvitrostudies